← Back to Screener
Quince Therapeutics, Inc. Common Stock (QNCX)
Price$1.37
Favorite Metrics
Price vs S&P 500 (26W)-101.42%
Price vs S&P 500 (4W)61.76%
Market Capitalization$22.33M
All Metrics
Book Value / Share (Quarterly)$0.19
P/TBV (Annual)2.10x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-7.15
Price vs S&P 500 (YTD)-100.05%
EPS (TTM)$-9.63
10-Day Avg Trading Volume21.87M
EPS Excl Extra (TTM)$-9.63
EPS (Annual)$-13.14
ROI (Annual)-127.80%
Cash / Share (Quarterly)$4.82
ROA (Last FY)-49.64%
EBITD / Share (TTM)$-4.01
ROE (5Y Avg)-79.44%
Cash Flow / Share (Annual)$-7.31
P/B Ratio21.09x
P/B Ratio (Quarterly)83.88x
Net Income / Employee (Annual)$-2
Net Interest Coverage (TTM)-33.67x
ROA (TTM)-50.80%
EPS Incl Extra (Annual)$-13.14
Current Ratio (Annual)6.05x
Quick Ratio (Quarterly)1.05x
3-Month Avg Trading Volume7.17M
52-Week Price Return-86.30%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$0.28
52-Week High$45.50
EPS Excl Extra (Annual)$-13.14
CapEx CAGR (5Y)33.77%
26-Week Price Return-92.67%
Quick Ratio (Annual)5.62x
13-Week Price Return-95.45%
Total Debt / Equity (Annual)0.48x
Current Ratio (Quarterly)1.12x
Enterprise Value$33.4
Revenue / Employee (Annual)$0
Cash / Share (Annual)$9.27
3-Month Return Std Dev688.81%
Net Income / Employee (TTM)$-2
ROE (Last FY)-188.51%
EPS Basic Excl Extra (Annual)$-13.14
Total Debt / Equity (Quarterly)16.54x
EPS Incl Extra (TTM)$-9.63
ROI (TTM)-181.44%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$4.98
Price vs S&P 500 (52W)-121.39%
Year-to-Date Return-95.91%
5-Day Price Return-2.84%
EPS Normalized (Annual)$-13.14
ROA (5Y Avg)-45.23%
Month-to-Date Return35.64%
Cash Flow / Share (TTM)$-0.78
EBITD / Share (Annual)$-13.75
LT Debt / Equity (Annual)0.48x
ROI (5Y Avg)-66.28%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-9.63
P/TBV (Quarterly)3.95x
P/B Ratio (Annual)2.73x
Book Value / Share (Annual)$6.85
Price vs S&P 500 (13W)-98.31%
Beta1.47x
Revenue / Share (TTM)$0.00
ROE (TTM)-370.46%
52-Week Low$0.80
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.17
2.64
2.33
2.33
Industry Peers — Biological Products(89)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
QNCXQuince Therapeutics, Inc. Common Stock | — | — | — | — | $1.37 |
AMGNAmgen Inc | 5.21x | 9.95% | 73.30% | 2.93% | $355.30 |
GILDGilead Sciences Inc | 5.80x | 2.40% | 78.83% | 133.64% | $137.64 |
ARGXargenx SE American Depositary Shares | 12.46x | 89.56% | 150.91% | — | $849.04 |
BNTXBioNTech SE American Depositary Share | 8.99x | -11.81% | 84.21% | — | $102.92 |
BIIBBiogen Inc. Common Stock | 2.63x | 2.22% | 75.69% | -18.77% | $177.35 |
MRNAModerna, Inc. Common Stock | 10.91x | -39.93% | 70.32% | — | $53.72 |
NBIXNeurocrine Biosciences Inc | 4.68x | 21.45% | 98.18% | 2.31% | $133.25 |
EXELExelixis Inc | 5.02x | 6.85% | 96.39% | 31.10% | $44.89 |
TECHBio-Techne Corp. | 7.62x | 1.64% | 66.60% | -20.58% | $59.23 |
HALOHalozyme Therapeutics, Inc. | 5.88x | 37.55% | 83.62% | 22.89% | $69.29 |
About
Quince Therapeutics is a preclinical-stage biopharmaceutical company developing a bone-targeting platform designed to deliver therapeutics directly to fracture and disease sites while reducing systemic side effects. The platform can accommodate small molecules, peptides, and large molecules. The company's pipeline includes programs in Ataxia-Telangiectasia and Duchenne Muscular Dystrophy, with expansion potential into additional indications.